GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Days Payable

Liquidia (Liquidia) Days Payable : 120.86 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia Days Payable?

Liquidia's average Accounts Payable for the three months ended in Mar. 2024 was $1.94 Mil. Liquidia's Cost of Goods Sold for the three months ended in Mar. 2024 was $1.47 Mil. Hence, Liquidia's Days Payable for the three months ended in Mar. 2024 was 120.86.

The historical rank and industry rank for Liquidia's Days Payable or its related term are showing as below:

LQDA' s Days Payable Range Over the Past 10 Years
Min: 166.81   Med: 1239.43   Max: 11554.81
Current: 166.81

During the past 8 years, Liquidia's highest Days Payable was 11554.81. The lowest was 166.81. And the median was 1239.43.

LQDA's Days Payable is ranked better than
52.91% of 722 companies
in the Biotechnology industry
Industry Median: 148.145 vs LQDA: 166.81

Liquidia's Days Payable declined from Mar. 2023 (211.94) to Mar. 2024 (120.86). It may suggest that Liquidia accelerated paying its suppliers.


Liquidia Days Payable Historical Data

The historical data trend for Liquidia's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Days Payable Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial 1,522.87 5,545.55 290.02 208.54 227.05

Liquidia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 211.94 187.60 298.56 147.40 120.86

Competitive Comparison of Liquidia's Days Payable

For the Biotechnology subindustry, Liquidia's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's Days Payable distribution charts can be found below:

* The bar in red indicates where Liquidia's Days Payable falls into.



Liquidia Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Liquidia's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (2.197 + 1.396) / 2 ) / 2.888*365
=1.7965 / 2.888*365
=227.05

Liquidia's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

Days Payable (Q: Mar. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2023 ) + Accounts Payable (Q: Mar. 2024 )) / count ) / Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=( (1.396 + 2.49) / 2 ) / 1.467*365 / 4
=1.943 / 1.467*365 / 4
=120.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liquidia Days Payable Related Terms

Thank you for viewing the detailed overview of Liquidia's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880